NCT01718938View on ClinicalTrials.gov

Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

February 28, 2014

Conditions
Gastroparesis
Interventions
DRUG

velusetrag dose 1

DRUG

velusetrag dose 2

DRUG

velusetrag dose 3

DRUG

placebo

Trial Locations (9)

23502

Digestive and Liver Disease Specialists, Norfolk

27612

Wake Research Associates, LLC, Raleigh

39202

GI Associates & Endoscopy Center, Jackson

46202

Indiana University Hospital, Indianapolis

65265

Center for Digestive and Liver Diseases, Inc., Mexico

85710

Desert Sun Clinical Research, Tucson

90036

Axis Clinical Trials, Los Angeles

93003

Ventura Clinical Trials, Ventura

97210

Northwest Gastroenterology Clinic, Portland

Sponsors

Collaborators (1)

Alfasigma S.p.A.
All Listed Sponsors
collaborator

Alfasigma S.p.A.

INDUSTRY

lead

Theravance Biopharma

INDUSTRY